A pivotal clinical trial co-led by Professor Nadia Harbeck, Director of the Breast Center at LMU University Hospital, has shown promising results in extending the lives of patients with advanced HER2-positive breast cancer, particularly those with brain metastases. The study, recently published in the journal, Nature Medicine, highlights the success of an innovative antibody-drug conjugate (ADC) called trastuzumab deruxtecan.
Login to read more